The FDA inspected and gave Mylan a clean bill of health. Mylan then sued the P-G, not once but twice, in a transparent attempt to find out who the paper's sources were. The suits appear to be an extension of an internal witchhunt for a mole who has been leaking bad news about the company. Coupled with that, Mylan's CFO left after just a few months on the job. The C-suite churn followed the 2007 exit of Mylan's COO, after it emerged her credentials were bogus. Mylan ended the year with a $121 million settlement with the Department of Justice regarding Medicaid rebates. The icing on the cake: Mylan's Dey unit staffers appear to be engaged in a civil war with the management that acquired them. 4. Elan (ELN) Elan holds two potentially amazing drugs, Tysabri for MS and bapineuzumab, an in-development Alzheimer's drug. Despite these blessings, management shoots itself in the foot at every step. They did a $1.4 billion financing deal with Johnson & Johnson that enraged Biogen, their equal partner on Tysabri.